Saturday 17 October 2026
Export STRO’s income statement to Excel — free account
Sutro Biopharma, Inc.
STRO Healthcare Biotechnology
Sutro Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $102.5 million, up 65.2% from fiscal 2024. In the quarter to June 2026, revenue fell 84.6%, EPS fell 66.4% and free cash flow grew 14.6%, each against the same quarter a year earlier.
10.94
0.52
−4.54%
Follow STRO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
12.04 | 3.27 | 0.96 | 0.70 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(14.37) | (7.71) | (3.72) | (1.93) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
8.61 | 1.32 | (0.34) | (0.81) | |
EV/EBITDA |
0.00 | 0.00 | 0.23 | 0.47 | |
EV/Operating CF |
(2.71) | (0.87) | 0.20 | 0.39 | |
EV/FCF |
(2.70) | (0.86) | 0.20 | 0.38 | |
Quick Ratio |
3.22 | 3.04 | 1.94 | 2.39 | |
Current Ratio |
3.32 | 3.12 | 2.01 | 2.53 | |
Net Debt/EBITDA |
5.65 | 7.03 | 3.83 | 3.54 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.20 | 0.35 | 0.37 | 0.32 | |
Operating CF/Net income |
0.99 | 1.10 | 0.57 | 0.67 | |
Capex/Depreciation |
0.00 | (0.01) | (0.17) | (0.22) | |
Research and Development Expense of Revenue |
322.14% | 251.69% | 314.60% | 411.15% | |
Selling, General and Administrative Expense of Revenue |
79.59% | 52.22% | 74.37% | 90.18% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
20.43% | 10.76% | 14.21% | 16.01% | |
Graham Net Nets |
(0.22) | (0.27) | (1.58) | (1.55) | |
Graham Number |
49.30 | 43.43 | 88.94 | 77.71 | |
Earnings Yield |
(52.18%) | (65.81%) | (194.93%) | (300.00%) | |
Free Cash Flow Yield |
(26.47%) | (46.69%) | (181.98%) | (304.88%) | |
Revenue per Share |
0.59 | 1.11 | 1.37 | 1.14 | |
Operating CF per Share |
(2.31) | (3.23) | (3.11) | (4.50) | |
Capex per Share |
0.00 | 0.00 | (0.02) | (0.03) | |
Free Cash Flow per Share |
(2.31) | (3.23) | (3.13) | (4.53) | |
Cash per Share |
9.92 | 15.48 | 16.64 | 19.75 | |
Shareholders Equity per Share |
(6.23) | (5.11) | (15.59) | (10.28) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(6.23) | (5.11) | (15.59) | (10.28) | |
Free Cash Flow |
(38.29) | (42.27) | (26.62) | (38.44) | |
Working Capital |
122.75 | 150.16 | 75.79 | 110.22 | |
Capital Expenditures |
0.00 | (0.01) | (0.18) | (0.25) | |
Net Current Asset Value |
(122.13) | (87.90) | (155.36) | (114.81) | |
EV/EBIT |
0.00 | 0.00 | 0.22 | 0.46 | |
Capex to Sales |
0.00 | 0.00 | 0.02 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
6.90 | 13.02 | 6.30 | 5.29 | |
Average Payables |
3.83 | 6.83 | 9.02 | 6.63 | |
Average Assets |
228.41 | 281.71 | 280.52 | 330.75 | |
Average Common Equity |
(67.71) | (46.35) | (43.93) | 11.98 |
Columns are period end dates